Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2023-12-18 00:00:00 ET · period of report 2023-12-14 · accession 0000950170-23-071116 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-18 | 2023-12-14+ | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $235.50 | -4,000 | 6,667 | -37% | -$942.0K |
| DM | 2023-12-18 | 2023-12-14+ | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.92 | +4,000 | 7,667 | +109% | +$351.7K |
| DM | 2023-12-18 | 2023-12-14+ | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $0.00 | -4,000 | 17.2K | -19% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-14 | S | D | 1,000 | $232.00 | 5,667 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-15 | M | A | 2,000 | $87.92 | 7,667 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-14 | S | D | 1,000 | $233.00 | 6,667 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-15 | S | D | 1,000 | $241.00 | 5,667 | D | — | — | |
| 5 | Common | Common Stock | 2023-12-15 | S | D | 1,000 | $236.00 | 6,667 | D | — | — | |
| 6 | Common | Common Stock | 2023-12-14 | M | A | 2,000 | $87.92 | 7,667 | D | — | — | |
| 7 | Derivative | Stock Option (Right to Buy) | 2023-12-14 | M | D | 2,000 | $0.00 | 19,200 | D | $87.92 · — to 2031-08-02 | 2,000 Common Stock | (F1) All shares issued pursuant to the exercise of the options reported herein represent 4,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |
| 8 | Derivative | Stock Option (Right to Buy) | 2023-12-15 | M | D | 2,000 | $0.00 | 17,200 | D | $87.92 · — to 2031-08-02 | 2,000 Common Stock | (F1) All shares issued pursuant to the exercise of the options reported herein represent 4,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |